Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 9, Issue 11, Pages 621-630Publisher
NATURE PORTFOLIO
DOI: 10.1038/nrclinonc.2012.159
Keywords
-
Categories
Funding
- National Institutes of Health, National Cancer Institute [P50 CA 58207]
- [U54 CA 112970]
- [K08CA137153]
Ask authors/readers for more resources
Massively parallel approaches to nucleic acid sequencing have matured from proof-of-concept to commercial products during the past 5 years. These technologies are now widely accessible, increasingly affordable, and have already exerted a transformative influence on the study of human cancer. Here, we review new features of cancer genomes that are being revealed by large-scale applications of these technologies. We focus on those insights most likely to affect future clinical practice. Foremost among these lessons, we summarize the formidable genetic heterogeneity within given cancer types that is appreciable with higher resolution profiling and larger sample sets. We discuss the inherent challenges of defining driving genomic events in a given cancer genome amidst thousands of other somatic events. Finally, we explore the organizational, regulatory and societal challenges impeding precision cancer medicine based on genomic profiling from assuming its place as standard-of-care.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available